Lumeon wins MedTech Breakthrough Award - Gilde Healthcare

Lumeon wins MedTech Breakthrough Award

7. Juni 2017

LONDON AND NEW YORK – Lumeon, a leading digital health company, has won the MedTech Breakthrough Award for Best Overall Health Administration Software. The awards recognize the top companies, people, platforms and products in the global health and medical technology market today.

Lumeon’s Care Pathway Management (CPM) platform, that allows providers to automate and orchestrate workflows across the care continuum, impressed the judges with its capability to digitize risk reducing strategies, improve efficiency and scale best practice.

Robbie Hughes, Lumeon’s CEO said, “Alternative payment models are prompting the industry to think differently about the way care is delivered and how we collaboratively manage risk to deliver better quality outcomes. Providers want better visibility into outcomes data across the care continuum, as well as innovative ways of engaging patients and managing healthcare administration. I’m delighted to accept this award as we continue to deliver solutions that are both personalized and scalable.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories. This year’s program attracted more than 2,000 nominations from over 10 different countries throughout the world. All nominations were evaluated by an independent panel of experts within the medical and health industry.

“We are pleased to recognize Lumeon among the MedTech Breakthrough Awards this year,” stated James Johnson, Managing Director at MedTech Breakthrough. “Health administration can be an extremely complex proposition for healthcare providers, taking focus away from the ultimate goal of improving patient care. By automating and simplifying health workflows with software such as Lumeon’s Care Pathway Management platform, we see tremendous benefits for healthcare providers and patients alike. Congratulations to the entire Lumeon team on their industry recognition.”

Gilde Healthcare participates in $150M Series D financing of CatalYm

Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international...
16. Juli 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
5. Juli 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
21. Mai 2024